Weekly Recap

NeurologyLive Weekly Recap

Each week on Saturday morning, the NeurologyLive^® team puts together a weekly recap that offers a quick look into some of the top headlines in neurology news that you may have missed.

Salanersen Shows Promise in Phase 1, MESA Open-Label Data Released, Fenfluramine Meets End Points in Phase 3 GEMZ Trial

Salanersen Shows Promise in Phase 1, MESA Open-Label Data Released, Fenfluramine Meets End Points in Phase 3 GEMZ Trial

NeurologyLive® Staff

Published: July 5th 2025 | Updated: July 5th 2025

Neurology News Network. for the week ending July 5, 2025. [WATCH TIME: 4 minutes]

Eptinezumab Improves Medication Overuse Headache, Submission for GTx-104 in Subarachnoid Hemorrhage, FDA Expands Indication for Vizamyl PET Imaging

Eptinezumab Improves Medication Overuse Headache, Submission for GTx-104 in Subarachnoid Hemorrhage, FDA Expands Indication for Vizamyl PET Imaging

NeurologyLive® Staff

Published: June 28th 2025 | Updated: June 28th 2025

Neurology News Network. for the week ending June 28, 2025. [WATCH TIME: 4 minutes]

Atogepant Outperforms Topiramate, IND Accepted for ORX142, Prasinezumab Heads to Phase 3 Parkinson Disease Studies

Atogepant Outperforms Topiramate, IND Accepted for ORX142, Prasinezumab Heads to Phase 3 Parkinson Disease Studies

NeurologyLive® Staff

Published: June 21st 2025 | Updated: June 21st 2025

Neurology News Network. for the week ending June 21, 2025. [WATCH TIME: 4 minutes]

Once-Nightly Oxybate Reduces Sleep-Related Eating, Samelisant Improves Excessive Daytime Sleepiness, Tirzepatide's Impact on OSA and Obesity

Once-Nightly Oxybate Reduces Sleep-Related Eating, Samelisant Improves Excessive Daytime Sleepiness, Tirzepatide's Impact on OSA and Obesity

NeurologyLive® Staff

Published: June 14th 2025 | Updated: June 14th 2025

Neurology News Network. for the week ending June 14, 2025. [WATCH TIME: 4 minutes]

RGX-202 Shows Continued Promise in DMD, AJ201 Meets End Points in Spinal and Bulbar Muscular Atrophy, Ponesimod Effect Sustained Over Long-Term

RGX-202 Shows Continued Promise in DMD, AJ201 Meets End Points in Spinal and Bulbar Muscular Atrophy, Ponesimod Effect Sustained Over Long-Term

NeurologyLive® Staff

Published: June 7th 2025 | Updated: June 7th 2025

Neurology News Network. for the week ending June 7, 2025. [WATCH TIME: 4 minutes]

ADDRESS-LC Study of Long COVID Initiated, Phase 4 Trial Testing IVIg Transition to Efgartigimod, Lack of Rebound Effect Seen in Ozanimod

ADDRESS-LC Study of Long COVID Initiated, Phase 4 Trial Testing IVIg Transition to Efgartigimod, Lack of Rebound Effect Seen in Ozanimod

NeurologyLive® Staff

Published: May 31st 2025 | Updated: May 31st 2025

Neurology News Network. for the week ending May 31, 2025. [WATCH TIME: 4 minutes]

Positive Phase 3 Data for Oral OSA Medication AD109, FDA Clears First Blood Test for Alzheimer Disease, DHE Autoinjector Treatment Approved for Migraine

Positive Phase 3 Data for Oral OSA Medication AD109, FDA Clears First Blood Test for Alzheimer Disease, DHE Autoinjector Treatment Approved for Migraine

NeurologyLive® Staff

Published: May 24th 2025 | Updated: May 24th 2025

Neurology News Network. for the week ending May 24, 2025. [WATCH TIME: 4 minutes]

AMX0035 Continues Promise in Wolfram Syndrome, FDA Clears Testing for CAP-002, Gene Therapy AAV-GAD Gains RMAT Designation

AMX0035 Continues Promise in Wolfram Syndrome, FDA Clears Testing for CAP-002, Gene Therapy AAV-GAD Gains RMAT Designation

NeurologyLive® Staff

Published: May 17th 2025 | Updated: May 17th 2025

Neurology News Network. for the week ending May 10, 2025. [WATCH TIME: 4 minutes]

EAP Program Authorized for ALS Agent SPG302, PTC518 Meets Primary End Point, Capricor Completes Mid-Cycle Review for Deramiocel

EAP Program Authorized for ALS Agent SPG302, PTC518 Meets Primary End Point, Capricor Completes Mid-Cycle Review for Deramiocel

NeurologyLive® Staff

Published: May 10th 2025 | Updated: May 10th 2025

Neurology News Network. for the week ending May 10, 2025. [WATCH TIME: 4 minutes]

FDA Approves STS101 for Acute Migraine, CALLIPER Trial Results Unveiled, Nipocalimab Gains FDA Approval for Myasthenia Gravis

FDA Approves STS101 for Acute Migraine, CALLIPER Trial Results Unveiled, Nipocalimab Gains FDA Approval for Myasthenia Gravis

NeurologyLive® Staff

Published: May 3rd 2025 | Updated: May 3rd 2025

Neurology News Network. for the week ending May 3, 2025. [WATCH TIME: 3 minutes]

GENERATION HD2 Trial Amended, NeuroOne Completes Submission for OneRF Ablation System, FDA Authorizes Implantable Continuous EEG Monitoring System

GENERATION HD2 Trial Amended, NeuroOne Completes Submission for OneRF Ablation System, FDA Authorizes Implantable Continuous EEG Monitoring System

NeurologyLive® Staff

Published: April 26th 2025 | Updated: April 26th 2025

Neurology News Network. for the week ending April 26, 2025. [WATCH TIME: 3 minutes]

Valtoco Gains Expanded Indication, FDA Approves Digital Therapeutic for Migraine, Phase 1 Study of AMX0114 in ALS Begins

Valtoco Gains Expanded Indication, FDA Approves Digital Therapeutic for Migraine, Phase 1 Study of AMX0114 in ALS Begins

NeurologyLive® Staff

Published: April 19th 2025 | Updated: April 19th 2025

Neurology News Network. for the week ending April 19, 2025. [WATCH TIME: 3 minutes]

Tividenofusp Alfa to be Submitted for Hunter Syndrome, Transcranial Stimulation Shows Efficacy in Alzheimer's, FDA Approves Pre-Filled Syringe for Efgartigimod

Tividenofusp Alfa to be Submitted for Hunter Syndrome, Transcranial Stimulation Shows Efficacy in Alzheimer's, FDA Approves Pre-Filled Syringe for Efgartigimod

NeurologyLive® Staff

Published: April 12th 2025 | Updated: April 12th 2025

Neurology News Network. for the week ending April 12, 2025. [WATCH TIME: 3 minutes]

Gamma Sensory Stimulation Preserves Corpus Callosum, P-Tau 217 and 181 Correlate With Clinical Outcomes, Lecanemab ARIA Risk Highest in Elevated Aß42/Total Tau Ratios

Gamma Sensory Stimulation Preserves Corpus Callosum, P-Tau 217 and 181 Correlate With Clinical Outcomes, Lecanemab ARIA Risk Highest in Elevated Aß42/Total Tau Ratios

NeurologyLive® Staff

Published: April 5th 2025 | Updated: April 5th 2025

Neurology News Network. for the week ending April 5, 2025. [WATCH TIME: 3 minutes]

HEALEY-ALS Platform Trial Amended, WVE-N531 Improves Muscle Growth in DMD, Diazoxide Choline Approved for Prader-Willi Syndrome

HEALEY-ALS Platform Trial Amended, WVE-N531 Improves Muscle Growth in DMD, Diazoxide Choline Approved for Prader-Willi Syndrome

NeurologyLive® Staff

Published: March 29th 2025 | Updated: March 29th 2025

Neurology News Network. for the week ending March 29, 2025. [WATCH TIME: 3 minutes]

New Study Testing Omaveloxolone in Pregnant Patients, Rozanolixizumab Improves Ocular Symptoms, Efgartigimod to be Studied in Juvenile MG

New Study Testing Omaveloxolone in Pregnant Patients, Rozanolixizumab Improves Ocular Symptoms, Efgartigimod to be Studied in Juvenile MG

NeurologyLive® Staff

Published: March 22nd 2025 | Updated: March 22nd 2025

Neurology News Network. for the week ending March 22, 2025. [WATCH TIME: 3 minutes]

Neflamapimod RewinD-LB Extension Data, CHMP Reaffirms Lecanemab Stance, Donanemab Associated With Increased ARIA Risk

Neflamapimod RewinD-LB Extension Data, CHMP Reaffirms Lecanemab Stance, Donanemab Associated With Increased ARIA Risk

NeurologyLive® Staff

Published: March 15th 2025 | Updated: March 15th 2025

Neurology News Network. for the week ending March 15, 2025. [WATCH TIME: 3 minutes]

Pilavapadin Improves Diabetic Peripheral Neuropathic Pain, Application of 2025 McDonald Criteria, FDA Expands Eculizumab Indication to Pediatrics

Pilavapadin Improves Diabetic Peripheral Neuropathic Pain, Application of 2025 McDonald Criteria, FDA Expands Eculizumab Indication to Pediatrics

NeurologyLive® Staff

Published: March 8th 2025 | Updated: March 8th 2025

Neurology News Network. for the week ending March 8, 2025. [WATCH TIME: 3 minutes]

FDA Approves Medtronic's Adaptive DBS, Hold Lifted on ELEVATE-44-102 Trial, Ecopipam Meets Primary and Secondary End Points in Tourette

FDA Approves Medtronic's Adaptive DBS, Hold Lifted on ELEVATE-44-102 Trial, Ecopipam Meets Primary and Secondary End Points in Tourette

NeurologyLive® Staff

Published: March 1st 2025 | Updated: March 1st 2025

Neurology News Network. for the week ending March 1, 2025. [WATCH TIME: 3 minutes]

Harmony Receives RTF Letter for Pitolisant, FDA Accepts Vatiquinone NDA, Gene Therapy SGT-003 Performs Well in Phase 1/2 Trial

Harmony Receives RTF Letter for Pitolisant, FDA Accepts Vatiquinone NDA, Gene Therapy SGT-003 Performs Well in Phase 1/2 Trial

NeurologyLive® Staff

Published: February 22nd 2025 | Updated: February 22nd 2025

Neurology News Network. for the week ending February 23, 2025. [WATCH TIME: 3 minutes]

NDA Accepted for Troriluzole, FDA Approves Mirdametinib for Neurofibromatosis, New Tablet Formulation for Risdiplam Approved

NDA Accepted for Troriluzole, FDA Approves Mirdametinib for Neurofibromatosis, New Tablet Formulation for Risdiplam Approved

NeurologyLive® Staff

Published: February 16th 2025 | Updated: February 16th 2025

Neurology News Network. for the week ending February 16, 2025. [WATCH TIME: 3 minutes]

Bexicaserin Improves Seizure Control in DEEs, SPN-830 Approved for Parkinson Disease, Self-Administration Rozanolixizumab Gains EU Approval

Bexicaserin Improves Seizure Control in DEEs, SPN-830 Approved for Parkinson Disease, Self-Administration Rozanolixizumab Gains EU Approval

NeurologyLive® Staff

Published: February 9th 2025 | Updated: February 9th 2025

Neurology News Network. for the week ending February 9, 2025. [WATCH TIME: 4 minutes]

MSA Agent ATH434 Shows Promising Phase 2 Data, FDA Approves Suzetrigine for Severe Acute Pain, AXS-07 Gains FDA Approval for Migraine

MSA Agent ATH434 Shows Promising Phase 2 Data, FDA Approves Suzetrigine for Severe Acute Pain, AXS-07 Gains FDA Approval for Migraine

NeurologyLive® Staff

Published: February 2nd 2025 | Updated: February 2nd 2025

Neurology News Network. for the week ending February 2, 2025. [WATCH TIME: 4 minutes]

FDA Accepts sNDA for Higher Dose Nusinersen, Tofersen Demonstrates Real-World Efficacy, Nipocalimab Gains Priority Review

FDA Accepts sNDA for Higher Dose Nusinersen, Tofersen Demonstrates Real-World Efficacy, Nipocalimab Gains Priority Review

NeurologyLive® Staff

Published: January 25th 2025 | Updated: January 25th 2025

Neurology News Network. for the week ending January 25, 2025. [WATCH TIME: 4 minutes]

FDA Accepts NDA for Lecanemab Subcutaneous Autoinjector, RAP-219 Shows Promise in Early Trials, Blarcamesine Treatment Effects Observed at 3 Years

FDA Accepts NDA for Lecanemab Subcutaneous Autoinjector, RAP-219 Shows Promise in Early Trials, Blarcamesine Treatment Effects Observed at 3 Years

NeurologyLive® Staff

Published: January 18th 2025 | Updated: January 4th 2025

Neurology News Network. for the week ending January 18, 2025. [WATCH TIME: 4 minutes]

Anti-Tau Therapy Posdinemab Gets Fast Track, Gene Therapy SGT-212 to Enter Friedreich Ataxia Trial, Zorevunersen Eyes Phase 3 Trial of Dravet

Anti-Tau Therapy Posdinemab Gets Fast Track, Gene Therapy SGT-212 to Enter Friedreich Ataxia Trial, Zorevunersen Eyes Phase 3 Trial of Dravet

NeurologyLive® Staff

Published: January 11th 2025 | Updated: January 4th 2025

Neurology News Network. for the week ending January 11, 2025. [WATCH TIME: 4 minutes]

Intrathecal Zolgensma Meets Primary End Point, Deramiocel BLA Submitted, Imlifidase Improves Function in Guillain-Barré Syndrome

Intrathecal Zolgensma Meets Primary End Point, Deramiocel BLA Submitted, Imlifidase Improves Function in Guillain-Barré Syndrome

NeurologyLive® Staff

Published: January 4th 2025 | Updated: January 4th 2025

Neurology News Network. for the week ending January 4, 2025. [WATCH TIME: 4 minutes]

FDA Places Hold on CONNECT2-EDO51, Sevasemten Meets End Point in Becker, Tolebrutinib Gets Breakthrough Therapy Designation

FDA Places Hold on CONNECT2-EDO51, Sevasemten Meets End Point in Becker, Tolebrutinib Gets Breakthrough Therapy Designation

NeurologyLive® Staff

Published: December 21st 2024 | Updated: December 21st 2024

Neurology News Network. for the week ending December 21, 2024. [WATCH TIME: 4 minutes]

RELIEV2-CM Study Launched, Dose-Finding Portion of ANQUR Underway, Anavex Submits EU Application for Blarcamesine

RELIEV2-CM Study Launched, Dose-Finding Portion of ANQUR Underway, Anavex Submits EU Application for Blarcamesine

NeurologyLive® Staff

Published: December 7th 2024 | Updated: December 7th 2024

Neurology News Network. for the week ending December 7, 2024. [WATCH TIME: 4 minutes]

Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB, Hearing Loss Independent Risk Factor for Parkinson

Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB, Hearing Loss Independent Risk Factor for Parkinson

NeurologyLive® Staff

Published: November 30th 2024 | Updated: November 30th 2024

Neurology News Network. for the week ending November 30, 2024. [WATCH TIME: 4 minutes]

1 2 3 4 5 6 7 8

...

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.